This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D69.1 | Synonyms: Platelet function disorder, Qualitative platelet disorder
Recognition of bleeding disorders caused by abnormal platelet function began in the early 20th century. In 1918, Glanzmann was the first to describe thrombasthenia, in which the platelet count is normal but aggregation function is lost, and this became the starting point of the concept of thrombocytopathy. Until the 1960s, platelet function disorders were classified under the general term 'thrombocytopathy'.
In the 1960s~1970s, with the development of light transmission aggregometry (LTA) by Born and O'Brien and others, detailed classification of platelet function disorders became possible. Subsequently, with advances in platelet membrane glycoprotein (GP) analysis, granule content analysis, and signal transduction pathway research, the molecular mechanisms of various thrombocytopathies were elucidated.
With the introduction of molecular genetic techniques in the 1990s and 2000s, the molecular classification of inherited thrombocytopathies became systematized. Thrombocytopathies are currently subdivided according to the site of the defect into membrane receptor defects, granule defects, signal transduction defects, secretion defects, and procoagulant activity defects.
In Korea, as the infrastructure for platelet function testing has been strengthened since the 1990s, cases of diagnosed inherited thrombocytopathy are increasing. In most cases secondary (acquired) platelet dysfunction is more common, and inherited thrombocytopathies belong to the rare disease category.
Inherited thrombocytopathies are caused by mutations in various genes involved in platelet function.
| Category | Representative disease | Causative gene |
|---|---|---|
| Membrane receptor defect | Glanzmann thrombasthenia | ITGA2B, ITGB3 |
| Membrane receptor defect | Bernard-Soulier syndrome | GP1BA, GP1BB, GP9 |
| Membrane receptor defect | P2Y12 receptor deficiency | P2RY12 |
| Alpha granule defect | Gray platelet syndrome | NBEAL2 |
| Dense granule defect | Hermansky-Pudlak syndrome | HPS1-11 |
| Dense granule defect | Chediak-Higashi syndrome | LYST |
| Procoagulant activity defect | Scott syndrome | TMEM16F(ANO6) |
Acquired thrombocytopathies are far more common than inherited ones. Major causes include drugs (aspirin, NSAIDs, clopidogrel, ticagrelor), uremia (chronic renal failure), liver cirrhosis, dysproteinemia (multiple myeloma, Waldenström macroglobulinemia), myeloproliferative neoplasms, and extracorporeal circulation.
Inherited thrombocytopathies show various modes of inheritance depending on the type of disease. These include autosomal recessive (Glanzmann thrombasthenia, Bernard-Soulier syndrome, most storage pool deficiencies), autosomal dominant (some platelet signal transduction defects), and X-linked (some storage pool deficiencies).
| Disease | Gene (location) | Mode of inheritance | Key features |
|---|---|---|---|
| Glanzmann thrombasthenia | ITGA2B(17q21.31), ITGB3(17q21.32) | AR | GPIIb/IIIa deficiency |
| Bernard-Soulier syndrome | GP1BA(17p13.2), GP1BB(22q11.21), GP9(3q21.3) | AR | Giant platelets, GPIb deficiency |
| Gray platelet syndrome | NBEAL2(3p24.3) | AR | Alpha granule deficiency |
| Hermansky-Pudlak syndrome | HPS1-11 | AR | Albinism, pulmonary fibrosis |
| P2Y12 receptor deficiency | P2RY12(3q24) | AR | Selective loss of ADP aggregation |
| Scott syndrome | TMEM16F(12q12) | AR | Impaired exposure of procoagulant phospholipids |
With the introduction of NGS panel testing, it has become possible to identify the molecular causes of complex thrombocytopathies that were previously difficult to diagnose. Platelet function disorder NGS panels can analyze more than 30 causative genes simultaneously.
The exact prevalence of inherited thrombocytopathies varies by disease type and is rare overall. Glanzmann thrombasthenia is about 1/1,000,000, Bernard-Soulier syndrome about 1/1,000,000, and storage pool deficiency is relatively more common, estimated at about 1/50,000.
Acquired thrombocytopathy is very common. Considering only the population using aspirin, a considerable proportion of the entire adult population experiences transient platelet dysfunction. Decreased platelet function is observed in about 50% of patients with chronic renal failure and in a considerable proportion of patients with liver cirrhosis.
In Korea, acquired platelet dysfunction frequently occurs due to drugs (antiplatelet agents) and chronic diseases (renal failure, liver disease). Inherited thrombocytopathies are classified as rare diseases, and accurate epidemiological statistics are lacking, but they are gradually being systematized through the rare disease registration system.
Platelet dysfunction can occur at several stages depending on the site of the defect.
Symptoms of thrombocytopathy differ according to the type and degree of platelet dysfunction, but mucosal bleeding is commonly characteristic. Epistaxis, ecchymosis, oral gum bleeding, menorrhagia, excessive bleeding after surgery/trauma, and gastrointestinal bleeding occur.
On physical examination, petechiae, purpura, and bruising are observed, and hepatosplenomegaly (some inherited syndromes), pallor (anemia from chronic bleeding), and albinism (Hermansky-Pudlak syndrome, Chediak-Higashi syndrome) may be found.
The platelet count is mostly normal, but in Bernard-Soulier syndrome and gray platelet syndrome, mild reduction and giant platelets are observed. Bleeding time and PFA-100/200 closure time are prolonged. On platelet aggregation testing (LTA), selectively reduced response to specific agonists appears depending on the site of the defect.
Giant platelets (Bernard-Soulier syndrome, gray platelet syndrome), reduced intraplatelet granules (gray platelet syndrome), and giant granule neutrophils (Chediak-Higashi syndrome) appear as specific findings.
Thrombocytopathy should be suspected in patients with recurrent mucosal bleeding despite a normal platelet count, patients with prolonged bleeding time, a history of recurrent bleeding beginning in childhood, and a family history of similar symptoms.
Complete blood count (CBC), platelet count, and peripheral blood smear are performed first. The platelet function analyzer (PFA-100/PFA-200) test is used as a simple first-line screening tool for platelet dysfunction. Coagulation tests (PT, aPTT) exclude coagulation factor abnormalities.
Acquired platelet dysfunction must be excluded by taking a medication history (aspirin, NSAIDs, antiplatelet agents), renal and liver function tests, and monoclonal protein testing.
LTA is the standard test for diagnosing platelet dysfunction. The stage of the defect is inferred by analyzing aggregation patterns using multiple agonists such as ADP, epinephrine, collagen, arachidonic acid, and ristocetin.
Membrane glycoprotein expression (CD41/GPIIb, CD61/GPIIIa, CD42b/GPIb, CD49b/GPVI) is quantified. The activation response is evaluated using activation markers (PAC-1, P-selectin/CD62P).
Transmission electron microscopy (TEM) evaluates platelet ultrastructure and the number and morphology of granules. Dense granule deficiency is confirmed by mepacrine staining. ATP release assay (lumi-aggregometer) evaluates dense granule release function.
A gene panel suited to the suspected disease (platelet function disorder NGS panel) is performed to identify causative gene variants. Specific variants are confirmed by Sanger sequencing, and deletions/duplications are detected by MLPA.
For acquired platelet dysfunction, stopping the causative drug, treating uremia (dialysis), and treating the underlying disease take priority. In inherited cases, treatment of the underlying disease itself is limited.
Tranexamic acid is used as first-line treatment for mild bleeding and for prophylactic use before procedures. Use before mucosal bleeding, dental procedures, and minor surgery is recommended.
DDAVP may be effective in patients with storage pool deficiency and some platelet signal transduction defects. It improves hemostasis through release of coagulation factor VIII and vWF.
Platelet transfusion is given for severe or life-threatening bleeding and for surgery. With repeated transfusions, HLA-matched platelets and leukoreduced platelets are used to minimize alloantibody formation.
rFVIIa is used when refractoriness to platelet transfusion develops or antibodies form. Its efficacy has been demonstrated in major inherited thrombocytopathies such as Glanzmann thrombasthenia and Bernard-Soulier syndrome.
Hermansky-Pudlak syndrome: nintedanib (FDA approved) is used when pulmonary fibrosis progresses. Chediak-Higashi syndrome and some storage pool deficiencies: allogeneic hematopoietic stem cell transplantation (HSCT) can be curative.
The prognosis of acquired thrombocytopathy is mostly good when the cause is corrected. The prognosis of inherited thrombocytopathy differs by disease type. Pure aggregation defects (Glanzmann thrombasthenia, etc.) can have a prognosis close to a normal lifespan with appropriate management.
Patients with Hermansky-Pudlak syndrome often die in their 50s because of pulmonary fibrosis complications. Chediak-Higashi syndrome has a poor prognosis without HSCT when lymphohistiocytosis (accelerated phase) develops.
When alloantibodies form after repeated transfusions, transfusion refractoriness develops and treatment options are limited, negatively affecting the prognosis.
Drugs that reduce platelet function, such as aspirin, NSAIDs, and clopidogrel, should be avoided. If their use is unavoidable, alternative drugs should be considered in consultation with a hematologist.
When there is a family history of inherited thrombocytopathy, genetic counseling is needed to confirm carrier status and plan pregnancy. Prenatal genetic testing (PGT-M, CVS, amniocentesis) is used when available.
In patients with chronic renal failure, uremic platelet dysfunction is minimized through renal function management and optimized dialysis. Iatrogenic platelet dysfunction (drug-induced) is prevented by regular medication review.